Recombinant Human CDCP1 Fc Chimera Protein, CF

When Recombinant Human CDCP1 Fc Chimera (Catalog # 10402-CU) is immobilized at 1 μg/mL (100 μL/well), Recombinant Human P-Cadherin Fc Chimera (Catalog # 861-PC) binds with an ED50 of 0.3-2.7 μg/mL.

2 μg/lane of Recombinant Human CDCP1 Fc Chimera (Catalog # 10402-CU) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 110-130 kDa and 220-260 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CDCP1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CDCP1 Fc Chimera (Catalog # 10402-CU) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human P-Cadherin Fc Chimera (Catalog # 861-PC) binds with an ED₅₀ of 0.3-2.7 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human CDCP1 protein
  

  Human CDCP1 (Phe30-Leu666) Accession # Q9H5V8.3	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q9H5V8.3
• N-terminal Sequence: Phe30
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 98 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 110-130 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CDCP1 Fc Chimera Protein, CF

• CD318 antigen
• CD318
• CDCP1
• CUB domain containing protein 1
• CUB domain-containing protein 1
• Membrane glycoprotein gp140
• SIMA135
• SIMA135TRASK
• Subtractive immunization M plus HEp3-associated 135 kDa protein
• Transmembrane and associated with src kinases

Background

CDCP1 (CUB-domain containing protein 1), also known as Trask or CD318, is a type I transmembrane receptor whose specific role remains unclear. Human CDCP1 is synthesized with a large extracellular domain (ECD) containing three CUB domains, a transmembrane domain and a cytoplasmic domain with 5 tyrosine phosphorylation sites (1). Full-length CDCP1 (Isoform 1) is ~135 kDa and can be cleaved into a ~70 kDa membrane-bound and a ~65 kDa circulating form (2). A secreted only form of human CDCP1, called Isoform 2, can also be expressed consisting of amino acids (aa) 30-343 of the ECD (3). The mature ECD of human Isoform 1 shares 84% aa sequence identity to mouse and rat CDCP1 Isoform 1. CDCP1 was originally identified from proteins involved in metastasis and has been found on tumor, stem cells, keratinocytes and colonic epithelial cells (1). Tyrosine phosphorylation of the intracellular domain of CDCP1 results in downstream signaling through Src-family kinases (SFKs), Akt, and PKCδ (2, 4, 5). CDCP1 appears to be important for cell-cell and cell-substratum adhesion and the phosphorylation state of CDCP1 regulates this effect (5, 7). CDCP1 is associated with a poor prognosis in epithelial tumors, such as lung, pancreatic, colorectal, renal, and ovarian carcinomas (rEf) and is a novel marker of the most aggressive human triple-negative breast cancers (7, 8). Several different extracellular forms of CDCP1 have been shown to exhibit disease-specific expression in prostate cancer (9).

1. Hooper, J.D. et al. (2003) Oncogene 22:1783.
2. He, Y. et al. (2010) J. Biol. Chem. 285:26162.
3. Perry, S.E. (2007) FEBS Lett. 581:1137.
4. Law, M.E. et al. (2016) Breast Cancer Res. 18:80.
5. Casar B. et al. (2012) Oncogene 31:3924.
6. Spassov, D.S. et al. (2013) Cancer Res. 73:1168.
7. Turdo, F. et al. (2016) Oncotarget 7:69649.
8. Wright, H.J. et al. (2016) Oncogene 35:4762.
9. Yang, L. et al. (2015) Oncotarget 6:43743.

Bioinformatics

• Uniprot:
  • Q9H5V8.3()